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Abstract: Extracellular Vesicles (EVs) have received considerable attention in recent years, both as
mediators of intercellular communication pathways that lead to tumor progression, and as potential
sources for discovery of novel cancer biomarkers. For many years, research on EVs has mainly
investigated either the mechanism of biogenesis and cargo selection and incorporation, or the
methods of EV isolation from available body fluids for biomarker discovery. Recent studies have
highlighted the existence of different populations of cancer-derived EVs, with distinct molecular cargo,
thus pointing to the possibility that the various EV populations might play diverse roles in cancer
and that this does not happen randomly. However, data attributing cancer specific intercellular
functions to given populations of EVs are still limited. A deeper functional, biochemical and
molecular characterization of the various EV classes might identify more selective clinical markers,
and significantly advance our knowledge of the pathogenesis and disease progression of many
cancer types.
Keywords: extracellular vesicles; exosomes; ectosomes; large oncosomes; microvesicles; cancer;
intercellular communication; tumor microenvironment
1. Introduction
Extracellular vesicles (EVs) are structures of variable size (from 30 nm to a few µm), surrounded
by a lipid bilayer, which are released from any type of cell into the extracellular space and are detectable
in body fluids. EVs can exert pleiotropic biological functions, and can influence the microenvironment
via the horizontal transfer of bioactive molecules, including proteins, lipids, DNA, and RNA [1,2].
EVs have been implicated in several physiological and pathological processes, such as inflammation,
immune disorders, neurological diseases, and cancer [3–5]. One of the first lines of evidence that tumor
cells shed membrane-vesicles was provided in 1978, when Friend and colleagues described them as
“rare, pleomorphic membrane-lined particles ranging broadly in size between 400 and 1200 Å”, in cell
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lines derived from patients with Hodgkin’s disease [6]. A year later an independent study identified
plasma-derived vesicles released by murine leukemia cells [7]. At the beginning of the 1980s, the
shedding of plasma membrane EVs from pig hepatocellular carcinoma and mouse breast carcinoma
cells helped to demonstrate that tumor EVs are carriers of procoagulant activity and thus participate in
cancer thrombogenicity by activating the clotting system [8]. However, only twenty years later it was
formally proven that EVs are not artifacts and can affect tumor progression by promoting angiogenesis,
tumor invasion, and immune escape [9,10]. Since then, the number of reports on cancer-derived EVs
has surged, and it is now well established that EVs contain functional proteins, microRNA, DNA, and
mutated transcripts with oncogenic properties. In particular, it has been proposed by several studies
that EV DNA may serve as a biomarker for cancer detection [11,12] and targeted therapy [13]. In
addition, this very active field of investigation recently culminated in the demonstration that EVs can
condition the pre-metastatic niche in vivo, a report that unequivocally corroborates active participation
of EVs in cancer lethality [14].
2. The Variegated World of Extracellular Vesicles
Tumor cells release several types of EVs, which differ in size, biogenesis, and molecular
composition. Two main categories of EVs have been described: exosomes and ectosomes. In addition,
recent data point to the existence of additional subpopulations of EVs, which may express
quantitatively and/or qualitatively different types of molecular cargo [15–18]. Moreover, Nakano
and colleagues have recently observed that different subtypes of glioblastoma may activate different
pathways of EVs biogenesis, due to the activation of diverse intracellular signaling [19].
Establishing an “EV population fingerprint” is highly relevant for two main reasons. On one
hand, the definition of specific biological roles associated with specific EV categories may significantly
advance our knowledge about the pathogenesis and the progression of disease. On the other hand,
a deeper functional, biochemical and molecular characterization of diverse populations of EVs might
identify more selective clinical markers, finely defining specific steps of tumorigenesis and potential
avenues for therapeutic intervention.
2.1. Exosomes
Exosomes are nano-sized EVs (30–100 nm) that originate from the late endosomal trafficking
machinery, are gathered intracellularly into multivesicular bodies (MVBs) and ultimately released
as a result of MVB fusion with the plasma membrane [20]. An analysis of the proteins most
frequently identified in exosomes and deposited in the online EV databases ExoCarta, Vesiclepedia and
EVPedia [21–25] highlights the presence of the tetraspanin family members CD9, CD63 and CD81, the
small actin-binding protein Cofilin1, heat shock proteins such as Hsp70 and Hsp90, and enzymes
involved in cell metabolism, including Enolase1, Aldolase A, phosphoglycerate kinase 1 (PGK1) and
lactate dehydrogenase A (LDHA) [26]. While most of these proteins have been shown to play a role
in cancer progression, their identification in exosomes is not specific for cancer. Additional proteins
that have more recently emerged as specifically associated with exosomes, and often absent in EVs
other than exosomes, are Tsg101 and Programmed Cell Death-6 Interacting Protein (PDCD6IP), also
known as ALG-2 Interacting Protein or, more commonly, as ALIX. Interestingly, these proteins are part
of the ESCRT complex (ESCRT I and ESCRT III, respectively) that has been recently shown to play a
direct role in exosomes biogenesis, with specific components differently affecting vesicle shedding [27].
While silencing of Tsg101 induces a decrease in exosomes production, the absence of ALIX leads to a
specific increase in the release of larger EVs [27], suggesting a role for both proteins in the biogenesis
of exosomes. However, conclusive results on the absence of Tsg101 and ALIX in non MVB-derived
EVs are still lacking, neither is it clearly known whether they can be identified in exosomes from all
cell systems, including cancer. Moreover, despite findings demonstrating that Tsg101 and ALIX can
interact, Tsg101 seems to play a direct role in cancer [28], whereas the function of ALIX is generally
associated with programmed cell death [29]. Interestingly, both genes are mostly mutated, albeit at
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extremely rare frequency, in human tumors, as demonstrated by data generated by the TCGA Research
Network (Available online: http://cancergenome.nih.gov/) (Figure 1).
2.2. Ectosomes
Ectosomes, also reported as membrane particles, nanoparticles, matrix vesicles and microvesicles
(MV), are cell surface-derived EVs typically larger than exosomes, originating from direct budding
from the plasma membrane [30]. This category includes apoptotic bodies (ABs) and possibly large
oncosomes (LO), which derive from apoptotic and non-apoptotic membrane blebbing processes,
respectively [31–33]. Ectosome shedding can be induced by alterations in the asymmetric distribution
of phospholipids in the plasma membrane, which results in the exposure of phosphatidylserine (PS)
and phosphatidylethanolamine (PE) in the extracellular layer of the membrane. This information
derives mostly from studies on MV [34,35] and the phenomenon of ectosome shedding is stimulated
by increased levels of intracellular Ca2+ in different cell types including cancer [36]. Cancer-derived
MV are enriched in the ADP-ribosylation factor 6 (ARF6), which functions as a promoter of EV
shedding from prostate and breast cancer cell lines [37]. Importantly, interrogation of publicly available
prostate cancer expression datasets demonstrates that ARF6 mRNA levels are higher in prostate cancer
compared with benign tissue [38].
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Figure 1. Genomic alterations of Tsg101 and ALIX in cancer. Frequency of copy number
alterations and mutations of Tsg101 (A); and ALIX (B) across several tumor types. The results
shown here are based upon data generated by the TCGA Research Network (Available online:
http://cancergenome.nih.gov/).
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Cancer ectosomes, similarly to other EV populations, represent a valuable reservoir for molecules
functionally involved in cancer progression and are representative of their cell of origin [37,39,40]
hence they make appealing candidates for the identification of circulating biomarkers. Despite the
similarities in the molecular composition of ectosomes and donor cells, it is becoming evident that
the internal composition of ectosomes, as well as the composition of the ectosome membrane, are
not a mere reflection of the cytosol and cell membrane of the cell of origin [37,39]. Unraveling the
mechanisms of molecular sorting in ectosomes could shed light on “intercellular messaging” that
might occur at high rates in cancer.
2.3. Apoptotic Bodies
Apoptotic bodies (ABs) are particles of relatively large size (1–4 µm), released by tumor cells
and other cell types upon the trigger of the cellular collapse that results in karyorrhexis (nuclear
fragmentation), increase in membrane permeability, and externalization of phosphatidylserine
(PS) [41,42]. Apoptotic membrane blebbing is a well-studied phenomenon that occurs during the
late stages of programmed cell death, and is the result of caspase-mediated cleavage and consequent
activation of ROCK1 [43]. It has been reported that ABs contain nuclear material, which might be
functional. However, the results suggesting that ABs, through the horizontal transfer of oncogenes
from cancer to recipient cells, participate in cancer development [44] needs further investigation in vitro
and possibly in vivo [45]. Importantly, although an exchange of cancer-derived DNA has been reported
in prostate cancer cells [46], whether this mechanism has functional consequences is still unknown.
Another role suggested for ABs is that they can act by “dispatching suicide notes” to the surrounding
environment. In fact, in early phases of apoptosis, AB membranes display increased permeabilization,
allowing them to release proteins into the microenvironment. This, in turn, prepares the surrounding
cells for the catastrophic loss of membrane integrity that affects apoptotic cells during secondary
necrosis [47].
2.4. Large Oncosomes
Large Oncosomes (LO) represent an additional class of tumor-derived EVs, so called because
of an atypically large size and abundant oncogenic cargo [31,38]. Similarly to ectosomes, this EV
population might originate directly from plasma membrane budding and, like MV, these particles
express ARF6 [38]. LO formation is particularly evident in highly migratory, aggressive tumor cells
with an amoeboid phenotype [31,38], and experiments in different cell lines indicate that LO can
form as bioproducts of non-apoptotic membrane blebs used by amoeboid cells as propulsive forces
to migrate [32]. Quantitative analyses of LO has shown that even if LO diameter can vary from 1 to
10 µm and larger, the mode of distribution of LO diameters, calculated on hundreds of cells, is 3–4 µm,
and some of them can reach several µm in size, considerably larger than any type of EV described so
far. LO have been identified in several cancer systems, and comparative experiments between tumor
and benign cells indicate that they are specifically released by tumor cells, whereas their detection in
benign cell systems is negligible. Consistently, LO-like features have been described in human prostate
cancer sections in situ, but not detected in benign tissue [38]. LO shedding is common to several
tumor types, including prostate, breast, bladder, lung cancer, and other tumors ([38] and unpublished
observations) and is enhanced by silencing of the gene encoding the cytoskeletal regulator Diaphanous
related formin-3 (DIAPH3), or by activation of the epidermal growth factor receptor (EGFR) and
overexpression of a membrane-targeted, constitutively active form of Akt1. Importantly, LO have been
identified in the circulation of mice and patients with metastatic prostate cancer, suggesting that these
EVs are potentially useful sources of clinical biomarkers [48].
EVs in the size range and appearance of LO have been recently described with different names
including: (1) giant vesicles, identified in ERα-positive breast cancer cells and tumor tissues [49];
(2) migrasomes, large round structures containing numerous vesicles (pomegranate-like structures),
which depart from retraction fibers of migratory benign cells [50]; and (3) tumor-derived MV
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originating from amoeboid-like tumor cells, in which VAMP3 seems to regulate the delivery of
MV cargo to regions of high plasma membrane blebbing. MV appear to be released through blebbing
during migration [51]. Whether these three types of EVs are distinct from LO and use different
mechanisms to play their extracellular functions is currently unknown.
Despite the effort to reach a consensus on vesicle nomenclature and classification, it is becoming
evident that the biochemical composition and the biological function of different EV populations
derived from the same cellular system overlap, at least in part [52]. Furthermore, current methods of
isolation do not discriminate between exosomes and ectosomes because physical properties that can
unambiguously distinguish between the two EV types have not been fully characterized and specific
molecular markers are still lacking [37,53,54]. However, despite the current limitations, a recent study
indicates that RNA profiles of exosomes, ectosomes, and ABs differ [55]. Therefore, regardless of
the confusing and frequently inappropriate terminology used to define particular EV populations,
it is clear that tumor cells release a spectrum of EVs that might all functionally participate in the
biology of the disease. A partial snapshot of the vesicle types described above is presented in Table 1.
A more comprehensive introduction into EVs, particularly exosomes, is provided in a focus edition by
Kalra et al. [56].
Table 1. Populations of Extracellular Vesicles.
Vesicle Type Size Origin Pathway Cargo Ref.
Exosomes 30–300 nm MVB fusion with theplasma membrane
Tsg101 and ALIX
dependent
Tsg101, ALIX, CD9,
CD63, CD81 [27,57]
Ectosomes 0.05–1 µm Budding from theplasma membrane
ARF6, RhoA, PS
exposure dependent ARF6 [37,40]
Apoptotic
Bodies 1–4 µm
Budding from the
plasma membrane
Apoptosis-related
pathway
Annexin V,
Caspase 3 [42]
Large
Oncosomes 1–10 µm
Budding from the
plasma membrane
EGFR, Akt1, Cav-1 and
DIAPH3-loss dependent
ARF6, CK18,
GAPDH [31,38,48]
Giant Vesicles 3–42 µm Budding from theplasma membrane
17-β-estradiol
dependent Not Identified [49]
Migrasomes 0.5–3 µm Budding fromretraction fibers
Integrin and migration
dependent TSPAN4 [50]
3. Cancer Extracellular Vesicles and the Tumor Microenvironment
The molecular mechanisms regulating the functional interaction between cancer cells and the
microenvironment have been the subject of active investigation, and historically are considered to be
mediated by small molecules, cytokines and growth factors. Today we know that cancer cells also
communicate through EVs, thus transferring functional information from cell to cell at the paracrine
level (Figure 2). Recent reports are leading to the conclusion that EV cargo influences the stroma
by activating molecular pathways that differ, at least in part, from the ones modulated by soluble
factors [58].
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Figure 2. Extracellular Vesicle (EV)-mediated interaction between cancer cells and different components
of the tumor microenviroment (Cancer Associated Fibroblasts—CAF, extracellular matrix—ECM,
Tumor cells, Endothelial cells, Immune system cells).
3.1. Cancer Cells and Cancer Associated Fibroblasts (CAFs)
Cancer associated fibroblasts (CAFs) are one of the most abundant cell type in the tumor
microenvironment. Upon exposure to cancer cells, CAFs alter their phenotypes [59]. In turn,
when co-cultured or exposed to conditioned media from CAFs, cancer cells demonstrate increased
aggressiveness, which might depend on CAF-induced stemness and metabolic reprogramming [60–63].
Both cancer cells and fibroblasts can produce different species of EVs, which seem to actively participate
in the mutual interplay between these cells, and this is crucial to tumor progression [58,64–67].
A recent study demonstrated that tumor-derived exosomes can modify the stroma to promote
tumor growth by supporting angiogenesis and accelerating tumor cell proliferation [58]. Furthermore,
the TGF-β associated with tumor exosomes can trigger fibroblast differentiation into a myofibroblast
or CAF phenotype, with increased levels of α-smooth muscle actin (α-SMA). The uptake of
tumor-derived exosomes by fibroblasts also results in the deposition of a hyaluronic acid pericellular
coat leading to increased contractile activity [64]. Similarly, treatment with ovarian and breast cancer
cell-derived exosomes induces, in adipose tissue derived stem cells, the typical characteristics of
tumor-associated myofibroblasts [68,69]. Additionally, the Extracellular Matrix Metalloproteinase
Inducer (EMMPRIN) [65] contained in exosomes and released by lung carcinoma cells is able to
enhance the expressionof Matrix Metalloproteases (MMPs) in fibroblasts, with dramatic repercussions
on tumor progression and metastasis.
Increasing attention has been placed to the role of cancer-derived ectosomes on the tumor
microenvironment. Tumor ectosomes have been reported as carriers of cathepsins [70], MMPs, uPA
and have been studied as promoters of the proteolytic cascade required by cancer cells to degrade
the extracellular matrix and invade the surrounding environment [71]. Antonyak and colleagues
demonstrated that ectosome-like MV, derived from different human cancer cells (breast carcinoma
and glioma cells), can transform normal fibroblasts and enhance their survival abilities by transferring
tissue transglutaminase (tTG), an enzyme that can cross-link Fibronectin (FN) on the ectosomes,
enhancing the role of FN in potentiating activation of integrins and their downstream effectors, focal
adhesion kinase (FAK) and ERK [72]. Additionally, LO can functionally influence the stroma, inducing
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Akt1 signaling pathway activation, expression of genes implicated in prostate cancer metastasis and
functional changes in cancer-associated fibroblasts [38,73].
Evidence that exosomes derived from fibroblasts exert a conditioning activity on cancer cells is still
very limited. One of the very first studies on the topic, showing that CAF-derived exosomes stimulate
breast cancer cell motility, protrusive activity and metastasis, was published in 2012 [66]. The salient
discovery of this seminal study is that CAF-derived exosomes can be taken up by breast cancer cells
and then loaded with Wnt11 produced by the recipient cells. This results in CAF-derived exosomes, in
which CD81 and Wnt11 colocalize in trans, which can activate planar cell polarity (PCP) signaling in
an autocrine manner in cancer cells, thus promoting migration. A more recent report demonstrates
that exosomes produced by dermal fibroblasts, in which the tissue inhibitor of MMPs (TIMP) gene
family has been knocked down with consequent acquisition of a CAF phenotype, are enriched in
Disintegrinand metalloproteinase domain-containing protein 10 (ADAM10), and can enhance breast
cancer cell motility by activating RhoA and Notch signaling [67]. Notably, mass spectrometry analysis
of fibroblast-derived exosomes indicates that these EVs stimulate migration and invasion of target
cells and can also play a role in metabolic reprogramming and extracellular acidification [66,67].
All together, these findings indicate that EVs can be exchanged reciprocally between cancer cells and
CAFs, and that most of the biological changes that occur in either compartment as a result of cancer
progression, including stemness, invasion, extracellular acidification, and metabolism reprogramming
are mediated by specialized EVs. However, comparative functional analysis of the functional influence
exerted by different populations of EVs on the stroma are still almost completely missing.
3.2. Immune System Regulation by Cancer Extracellular Vesicles
The uptake of tumor derived EVs by immune cells seems to have functional consequences on the
immune microenvironment, which can result in either escaping the immune response or in activating
immune suppression. Whether different populations of EVs elicit distinct types of immune responses,
and the molecular mechanisms underlying the transferring to and the modulation of the immune
microenvironment by receptors, proteins, RNA, and DNA carried in EVs, are all still largely unknown.
Nonetheless, studying how immune cells are educated by tumor-derived EVs, thus facilitating tumor
cell escape strategies, is crucial in order to develop cancer vaccines and new cancer treatments.
One way tumor EVs educate the immune microenvironment is by transfer of information to
monocytes. Baj-Krzywirzeka and colleagues [74] characterized a number of cell surface markers and
mRNA transcripts in EVs from pancreatic adenocarcinoma (HPC-4), colorectal carcinoma (DeTa), and
lung carcinoma (A549) cells and they found that IL8, VEGF, HGF, and CD44 mRNA were expressed at
high levels in EVs, suggesting a function for these messengers in monocyte re-education. Moreover,
the interaction of EV cell surface proteins with monocytes alters CCR6 and CD44v7/8 expression and
activates Akt, resulting in increased chemo-taxis and cell survival. All these events may result in the
recruitment of monocytes into the tumor tissue, where they can differentiate into tumor-associated
macrophages and support tumor initiation, local progression, and distant metastasis [75].
Frequent targets of tumor-derived exosomes are CD8+ T lymphocytes. Wieckowski and
colleagues [76] demonstrated that MV from head and neck squamous cell carcinoma (PCI-13) carry
the cancer testis antigen MAGE 3/6, and FasL that, once transferred to CD8+ T cells, induce their cell
death. Another study demonstrated that EVs can be collected from the sera of patients with acute
myeloid leukemia (AML), which contains higher levels of membrane associated TGFβ-1 and FasL than
control sera [77] and that the treatment of Natural Killer cells with AML patients’exosomes results
in TGFβ-1-mediated cytotoxicity of the target cells. On the other hand, tumor exosomes have also
the ability to induce immune suppression by activating CD4+/CD25+Foxp3+ regulatory T cells (Treg)
via TGFβ-1.
The induction of an efficient adaptive immune response against the tumor requires dendritic cell
cross-processing and presentation of tumor antigens to T cells. Rughetti and colleagues characterized
a population of EVs containing the tumor associated MUC1, a glycoprotein that can bind the MHC
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groove and induce activation of CD8+ T cells, which can influence its processing, in dendritic cells.
Importantly, dendritic cells can also internalize MUC1-positive EVs obtained from ascites of patients
with stage III or IV ovarian cancer [78]. It is evident that, by eliminating the lymphocytes that have
the ability to recognize and kill tumor cells, or by activating the regulatory suppressive branch of the
adaptive response, cancer can escape immune attack and enhance its own survival [79].
3.3. Cancer Extracellular Vesicles and the Endothelium
The genesis of new blood vessels, known as angiogenesis, is an important step in cancer
progression. Establishing the tumor vascular network is essential for cancer cell proliferation because
tumor cells depend on blood for the supply of oxygen and nutrients and for the removal of waste
products. The vascular supply becomes even more crucial to the cells during metastatic invasion, and
facilitates the entrance of tumor cells in the bloodstream to colonize distant organs in the body [80,81].
Importantly, tumor exosomes contain key pro-angiogenic factors directly linked to endothelial
cell migration and the induction of new blood vessel formation, such as Vascular Endothelial Growth
Factor (VEGF), overexpressed in the majority of tumors [82,83], Epidermal Growth Factor like domains
(EDIL-3/Del1) in bladder cancer cell-derived exosomes [84] and Annexin A2 (ANXA2), one of the
most abundant proteins of glioblastoma cell-derived exosomes [85]. Kucharzewska and colleagues
showed that exosomes derived from glioblastoma cells in hypoxic conditions are potent inducers of
angiogenesis through phenotypic modulation of endothelial cells [86]. Furthermore, it has been shown
that exosomes derived from renal cancer cells induce up-regulation of VEGF mRNA and protein levels
in human umbilical vein endothelial cells (HUVECs), thus promoting angiogenesis [87].
Recent studies have demonstrated that tumor exosomes contribute to angiogenesis by transferring
miRNAs [88]. Taverna and colleagues reported that exosomes derived from chronic myeloid leukemia
are enriched with miR-126, which can be delivered to endothelial cells and down-regulate its
molecular targets, CXCL12 and VCAM1. This results in enhanced migration of the cancer cells
toward the endothelial cells in a co-culture model [89]. The release of exosomes enriched with
miR-92a from leukemic cells induces down regulation of integrin α5 in endothelial cells and increases
angiogenesis [90]. Additionally, exosomes derived from lung adenocarcinoma, enriched with miR-210,
promote tube formation in HUVECs by down-regulating its target Ephrin A3, a known inhibitor of
angiogenesis [91].
Recently, a functional role for large oncosomes (LO) in endothelial cell signaling and activities
has been described: LO have been observed to induce migration of mouse dermal endothelial
(MDEC) and tumor endothelial cells (TEC), suggesting that these EVs might disrupt the integrity
of endothelial cell junctions and thereby increase blood vessel permeability in vivo [38]. However,
additional studies to test whether the results on endothelial cell migration can be reproduced by using
canonical angiogenesis assays in vitro are needed to fully understand the biological consequences of
the cross-talk between LO and the endothelium. Further experiments are also necessary to determine
if these atypically large EVs can be internalized into endothelial cells. Finally, although it has been
demonstrated that LO extracted from the plasma of mice with prostate cancer can stimulate migration
of endothelial cells, the capability of these EVs to cause endothelial leakage in animal models has yet
to be tested. Additionally, the molecular mechanisms underscoring this and other biological functions
of LO are still largely unknown [38].
While different EV populations have been studied and demonstrated to be involved in
angiogenesis, whether they cooperate or not, and to what extent each population intervenes in
specific phases of angiogenesis and metastasis is still a topic of investigation.
3.4. Extracellular Vesicles and the Transfer of Biological Information between Cancer Cells
EV-mediated intercellular communication is not limited to the interactions between tumor
cells and the microenvironment described above, but rather occurs within the composite puzzle
of heterogeneous cells that populate the tumor. Among the different roles EVs can play in extracellular
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communication in cancer, one fascinating hypothesis is that EVs might function by horizontal transfer
of genes with pre-existent mutations. While the intercellular transfer of oncogenic DNA has often
been attributed to the uptake of apoptotic bodies (ABs) [44], reports indicate that EV populations
corresponding to exosome and MV subtypes can mediate single- and double-stranded DNA transfer
respectively [92,93]. In particular, H-ras-transformed rat epithelial cells can shed EVs containing
chromatin-associated double-stranded DNA fragments covering the entire host genome, which can
transfer full-length H-ras to recipient cells, stimulating their proliferation and inducing phenotype
changes [92]. Another emerging important function seems to be related to the transfer and propagation
of drug resistance. Almost unavoidably, chemotherapy results in changes in the biology of cancer
cells, which consequently leads to chemoresistance. The traditional view believes that cells with
endogenously acquired chemoresistance will survive and propagate upon treatment. In addition, a new
hypothesis suggests that chemoresistance can also be transmitted horizontally from one cell to another
through the exchange of EVs. Indeed, Zhang and colleagues recently described EV-mediated transfer
of resistance to Paclitaxel in ovarian cancer [94]. P-glycoprotein (P-gP), encoded by the multidrug
resistance gene-1 (MDR-1), which is associated with resistance to a variety of anticancer agents, is
delivered through EVs from resistant to sensitive cells that then acquire the resistant phenotype.
Using a different mechanism, exosomes can indirectly modulate P-gP by transferring to recipient cells
TrpC5, a Ca2+ permeable channel [95]. This leads to increased concentrations of intracellular Ca2+ and
consequent increase of P-gP levels, and intercellular transfer of drug resistance. This seems to occur
between different cell types, including cancer and endothelial cells [96]. Intriguingly, an additional
novel molecular mechanism by which sensitive cells become chemoresistant via exosome-mediated
horizontal communication is mediated by miRNA and other non-coding RNAs [97]. For example,
miR-222, which is cargo of breast cancer exosomes can target PTEN, thus activating the PI3K pathway,
stimulating cell proliferation and promoting chemoresistance to Adryamycin and Docetaxel in cells
sensitive to these drugs. However, the specific mechanism by which the sensitive cells became resistant
is not known [98]. EVs can also play a protective role in chemoresistance. This is the case for a study
demonstrating that EVs can be directly involved in the sequestration, transport and expulsion of
Cisplatin from cancer cells [99], suggesting that, by using a sophisticated disposal mechanism, cancer
cells might escape drug treatments.
In the future, it would be useful to investigate the extent to which specific types of EVs are
implicated in drug chemoresistance and if the transfer of entire genes can modify the genomic make
up of the recipient cells thus modulating response to the drugs intrinsically, before initiating drug
treatment [100]. Further information on various aspects of EVs is provided in the other reviews of this
focus edition [56,101–104].
4. Extracellular Vesicle Associated Cargo with Particular Emphasis on MicroRNA
The molecular content of EVs seems to be highly dependent on the source and conditions of the
system at the time of vesicle biogenesis. For example, the abundance of the RNA and protein content
of endothelial cell-derived exosomes is altered after exposure of the endothelial cells to different types
of stress, including hypoxia, treatment with TNFα, or exposure to high concentrations of glucose and
mannose [105]. Moreover, the overexpression of the ErbB2/HER2 receptor tyrosine kinase can alter
the proteome of two different populations of EVs derived from mammary luminal epithelial cell lines
in comparison with parental cells, suggesting complementary roles for certain biological pathways,
and possibly a different response to HER2 upregulation in different types of EVs [106]. A plethora
of studies arose on proteomic analyses of EVs from different organ systems [107,108], as it has been
discussed by recent reviews [109].
Particular attention has recently been paid to the study of microRNAs (miRNAs) as key regulatory
molecules in several diseases, including cancer. In bodily fluids, miRNAs have been identified either
in complex with the argonaute RISC catalytic factor AGO2 [110,111] or within EVs [39,112]. Kosaka
and colleagues demonstrated that incorporation of miRNA into intraluminal vesicles of MVBs is
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controlled by neutral sphingomyelinase 2 (nSMase2), a regulator of ceramide biosynthesis [113].
Exosome shedding is potentiated by nSMase2, and its inhibition reduces the release of exosomes
containing miRNA. This result has been confirmed in another study, demonstrating that RAB27A and
RAB27B, two small GTPases that regulate secretory pathways, increase miRNA export from bladder
carcinoma cells [114]. Vallarroya-Beltri and colleagues demonstrated that the miRNA sequence motif is
important for miRNA loading into exosomes. This conclusion derives from mutagenesis experiments
demonstrating that the heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) binds miRNAs
directly through the recognition of their mature sequence, and controls their sorting in EVs. In
exosomes, hnRNPA2B1 is sumoylated, and this post-translational modification facilitates its binding to
miRNAs [115]. The EV-loading efficiency seems to depend not only on the RNA sequence but also on
the cell type and physiological state. As a consequence, some small RNAs appear to be preferentially
exported into EVs, while others are retained within the cell [116]. Whether these crucial mechanistic
insights are applicable to cancer EVs remains to be proven.
Numerous studies have reported enrichment of miRNAs in EVs released by different types of
cancer cells and present in biological fluids from cancer patients, resulting in the identification of
promising markers of disease prognosis [117]. These EV miRNAs also play a functional role that is
becoming increasingly recognized. A recent study suggests that decreased export of tumor suppressor
miRNAs might be a mechanism of pro-metastatic function exerted by EVs in vivo [114]. One example
is represented by miR-200, highly expressed in EVs from metastatic breast cancer cell lines, and
responsible for enhanced metastatic abilities of less aggressive cells upon intercellular transfer [118].
Remarkably, Melo and colleagues have recently demonstrated the presence, in cancer but not in
normal cell-derived exosomes, of AGO2 that, together with the RISC-Loading Complex (RLC), display
cell-independent capacity to process pre-miRNAs in mature transcripts [119]. This study provides
evidence that cancer exosomes, including those derived from breast cancer patient sera, can confer
tumorigenic behavior to epithelial cells in a Dicer-dependent manner, and strongly reinforces the
rationale for the development of exosome based therapies.
Surprisingly, the first quantitative and stoichiometric evaluation of exosome-derived miRNA
demonstrates the presence of less than one miRNA copy per exosomes [120]. The authors propose
two alternative models, a low-occupancy/low-miRNA concentration model, where a small number of
exosomes carries a low concentration of miRNA, and a low-occupancy/high-miRNA concentration
model, where rare exosomes carry many copies of a given miRNA. This study highlights the necessity
to expand our current methodologies and approaches to more deeply investigate the functional role of
EV miRNA cargo along with its potential use as a biomarker. It also corroborates the hypothesis that
large EVs might contain higher amounts of miRNA [73]. Quantification of miRNA in EVs is an exciting
topic in cancer research also because the amount of extracellular miRNA seems to be upregulated in
the plasma of patients bearing tumors [121,122].
5. Conclusions
EVs are involved in several, if not all aspects, of tumor development and progression due to
their apparently fundamental role in packaging and delivering molecular messages intercellularly.
The potential implications, both diagnostic and therapeutic, of a deeper EV characterization, are
widespread. Despite the current limitations, our abilities to specifically characterize EV populations are
constantly improving. Furthermore, different EVs might all coexist at the same time within the tumor
microenvironment and possibly cooperate or antagonize each other in the intercellular exchange of
messages. In line with this concept, it might be helpful to functionally study different EV populations
in a comparative manner or in combination. Finally, additional studies are necessary to clarify whether
EV release is primarily a mechanism for spreading cancer-associated activities within the tumor
microenvironment and in the circulation, if it is a mechanism of defense adopted by cancer cells to
survive during disease progression, or both.
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